Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
Aditya BagrodiaJohn T LafinJeffrey HowardThomas GeraldArmon AminiAnna SavelyevaSolomon L WolduCheryl M LewisLiwei JiaVitaly MargulisNicholas ColemanCinzia ScarpiniA Lindsay FrazierMatthew Jonathan MurrayJames F AmatrudaAditya BagrodiaPublished in: Andrology (2022)
MiR-371a-3p outperformed STMs in the primary RPLND settings. However, miR-371a-3p was not a robust predictor of pathology in the PC setting. These results suggest that pure seminoma at RPLND is a clinical context, wherein the miRNA assay may require further refinement.